全文获取类型
收费全文 | 37082篇 |
免费 | 2631篇 |
国内免费 | 491篇 |
专业分类
耳鼻咽喉 | 154篇 |
儿科学 | 496篇 |
妇产科学 | 550篇 |
基础医学 | 1744篇 |
口腔科学 | 285篇 |
临床医学 | 3402篇 |
内科学 | 4211篇 |
皮肤病学 | 478篇 |
神经病学 | 1233篇 |
特种医学 | 497篇 |
外科学 | 1930篇 |
综合类 | 3951篇 |
现状与发展 | 1篇 |
一般理论 | 10篇 |
预防医学 | 7214篇 |
眼科学 | 198篇 |
药学 | 10920篇 |
14篇 | |
中国医学 | 626篇 |
肿瘤学 | 2290篇 |
出版年
2023年 | 545篇 |
2022年 | 934篇 |
2021年 | 1440篇 |
2020年 | 1278篇 |
2019年 | 1264篇 |
2018年 | 1219篇 |
2017年 | 1169篇 |
2016年 | 1171篇 |
2015年 | 1320篇 |
2014年 | 2689篇 |
2013年 | 3322篇 |
2012年 | 2542篇 |
2011年 | 2877篇 |
2010年 | 2125篇 |
2009年 | 2040篇 |
2008年 | 2004篇 |
2007年 | 1891篇 |
2006年 | 1577篇 |
2005年 | 1269篇 |
2004年 | 1034篇 |
2003年 | 851篇 |
2002年 | 665篇 |
2001年 | 583篇 |
2000年 | 542篇 |
1999年 | 511篇 |
1998年 | 329篇 |
1997年 | 326篇 |
1996年 | 241篇 |
1995年 | 241篇 |
1994年 | 238篇 |
1993年 | 175篇 |
1992年 | 172篇 |
1991年 | 121篇 |
1990年 | 125篇 |
1989年 | 95篇 |
1988年 | 111篇 |
1987年 | 98篇 |
1986年 | 104篇 |
1985年 | 119篇 |
1984年 | 124篇 |
1983年 | 72篇 |
1982年 | 72篇 |
1981年 | 56篇 |
1980年 | 64篇 |
1979年 | 49篇 |
1978年 | 56篇 |
1977年 | 53篇 |
1976年 | 59篇 |
1975年 | 65篇 |
1974年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
目的:研究乙酰紫草素(ASK)对人前列腺癌PC-3细胞的诱导凋亡作用及相关的分子机制。方法:利用CCK-8实验检测ASK对体外培养PC-3细胞的杀伤作用;利用流式细胞术实验检测ASK处理后PC-3细胞凋亡情况;利用Western blotting检测凋亡蛋白和AKT信号通路蛋白的表达。结果:CCK-8实验证明ASK能够以时间和浓度依赖性抑制前列腺癌PC-3细胞的增殖;流式细胞术实验证明ASK能够诱导人前列腺癌PC-3细胞线粒体依赖性凋亡;Western blotting证明ASK能够有效抑制前列腺癌PC-3细胞中的AKT信号通路。结论:ASK能够有效抑制人前列腺癌PC-3细胞增殖,并能够有效诱导PC-3细胞发生线粒体依赖性凋亡,其机制可能是通过调控PI3K/Akt信号通路来实现,说明ASK具有一定的抗前列腺癌的潜力。 相似文献
92.
93.
《Actas dermo-sifiliográficas》2022,113(6):543-549
BackgroundCutaneous manifestations are complicated to treat in rare diseases. The main aim of this study was to analyze the impact of compounded drugs prepared by hospital pharmacists on the quality of life of patients with genodermatoses.Material and methodsWe undertook a cross-sectional study of patients with genodermatoses treated with topical medications compounded and dispensed by the pharmacy at Complejo Hospitalario Universitario in Pontevedra, Spain. We collected demographic data and answers to questionnaires examining generic and disease-specific quality of life, treatment satisfaction, and treatment adherence.ResultsNine patients were included. We observed a significant improvement in health-related quality of life following treatment with compounded drugs. Satisfaction with the topical medications was 2.8 on a scale of 0 (greatest satisfaction) to 25. Treatment adherence was 59%.ConclusionsDrug compounding facilitates access to orphan drugs that are not available for many rare diseases. Few studies, however, have analyzed impact on quality of life in this setting. In this series of patients with genodermatoses, topical medications compounded and dispensed by a hospital pharmacy improved health-related quality of life. This preliminary study has given rise to a multicenter study of compounding for ichthyosis. We expect that analysis of a larger sample will confirm our findings. 相似文献
94.
《Health policy (Amsterdam, Netherlands)》2020,124(9):984-990
Previous studies on changes in health policies theorize such changes either as crises responses, or as the outcome of longer-term stakeholder conflicts. In this paper, we propose that parliaments function as overlooked, intermediate actors that contribute to translating the interests of stakeholders into policy changes. We study the role of parliament connecting policy makers and stakeholders in the context of drug regulation. Based on three high-profile cases of drug withdrawals between 1991 and 2005 in the United Kingdom (triazolam, rofecoxib, and co-proxamol), we distinguish partisan-political, individual-idiosyncratic, and collective-institutional pathways of parliamentary action on drug withdrawals. Distinguishing direct and indirect actions, we argue that indirect courses of action, including advocacy and educational work, can be just as effective as regular legislative endeavours, under certain conditions. 相似文献
95.
96.
《Clinical genitourinary cancer》2020,18(1):1-10
Many therapeutic options are now available for men with metastatic castration-resistant prostate cancer (mCRPC), including next-generation androgen receptor axis-targeted therapies (AATTs), immunotherapy, chemotherapy, and radioisotope therapies. No clear consensus has been reached for the optimal sequencing of treatments for patients with mCRPC, and few well-validated molecular markers exist to guide the treatment decisions for individual patients. The androgen receptor splice variant 7 (AR-V7), a splice variant of the androgen receptor mRNA resulting in the truncation of the ligand-binding domain, has emerged as a biomarker for resistance to AATT. AR-V7 expression in circulating tumor cells has been associated with poor outcomes in patients treated with second- and third-line AATTs. Clinically validated assays are now commercially available for the AR-V7 biomarker. In the present review of the current literature, we have summarized the biology of resistance to AATT, with a focus on the AR-V7; and the clinical studies that have validated AR-V7 expression as a strong independent predictor of a lack of clinical benefit from AATTs. Existing evidence has indicated that patients with AR-V7–positive mCRPC will have better outcomes if treated with taxane chemotherapy regimens rather than additional AATTs. 相似文献
97.
《Clinical lung cancer》2020,21(3):232-237
BackgroundInsights into the mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further patient management, including the choice of second-line treatment. The EGFR T790M mutation is the most common mechanism of resistance to first- and second-generation EGFR TKIs. Owing to its biologic relevance in the response of non–small-cell lung cancer (NSCLC) to the selective pressure of treatment, the present study investigated whether the occurrence of T790M at progression differed among patients receiving gefitinib, erlotinib, or afatinib.Patients and MethodsThe present retrospective study included patients with NSCLC with an EGFR activating mutation, who had received gefitinib, erlotinib, or afatinib as first-line treatment. Plasma samples for the analysis of cell-free DNA were taken at disease progression and analyzed using a digital droplet polymerase chain reaction EGFR mutation assay.ResultsA total of 83 patients were enrolled; 42 had received gefitinib or erlotinib and 41afatinib. The patient characteristics were comparable across the 2 groups. The median time to progression (TTP) was 14.4 months for the gefitinib and erlotinib group and 10.2 months for the afatinib group (P = .09). Of the 83 patients, 47 (56.6%) were positive for the T790M in plasma. A greater incidence of T790M was observed in patients with progression during gefitinib or erlotinib therapy compared with patients treated with afatinib (33 [79%] vs. 14 [34%], respectively; odds ratio, 7.1; 95% confidence interval, 2.7-18.5; P = .0001).ConclusionsAlthough gefitinib, erlotinib, and afatinib showed a comparable TTP in patients receiving first-line therapy, the incidence of T790M differed among them, as demonstrated by the present study, which could have implications for the choice of second-line treatment. 相似文献
98.
Jin Ge Emily R. Perito John Bucuvalas Richard Gilroy Evelyn K. Hsu John P. Roberts Jennifer C. Lai 《American journal of transplantation》2020,20(4):1116-1124
Split liver transplantation (SLT) is 1 strategy for maximizing the number of deceased donor liver transplants. Recent reports suggest that utilization of SLT in the United States remains low. We examined deceased donor offers that were ultimately split between 2010 and 2014. SLTs were categorized as “primary” and “secondary” transplants. We analyzed allocation patterns and used logistic regression to evaluate factors associated with secondary split discard. Four hundred eighteen livers were split: 54% from adult, 46% from pediatric donors. Of the 227 adult donor livers split, 61% met United Network for Organ Sharing “optimal” split criteria. A total of 770 recipients (418 primary and 352 secondary) were transplanted, indicating 16% discard. Ninety‐two percent of the 418 primary recipients were children, and 47% were accepted on the first offer. Eighty‐seven percent of the 352 secondary recipients were adults, and 7% were accepted on the first offer. Of the 352 pairs, 99% were transplanted in the same region, 36% at the same center. In logistic regression, shorter donor height was associated with secondary discard (odds ratio 0.97 per cm, 95% CI 0.94‐1.00, P = .02). SLT volume by center was not predictive of secondary discard. Current policy proposals that incentivize SLT in the United States could increase the number of transplants to children and adults. 相似文献
99.
100.
《Journal of Pharmaceutical Analysis》2020,10(5):434-443
As a powerful tool to advance drug discovery, molecular imaging may provide new insights into the process of drug effect and therapy at cellular and molecular levels. When compared with other detection methods, fluorescence-based strategies are highly attractive and can be used to illuminate pathways of drugs’ transport, with multi-color capacity, high specificity and good sensitivity. The conjugates of fluorescent molecules and therapeutic agents create exciting avenues for real-time monitoring of drug delivery and distribution, both in vitro and in vivo. In this short review, we discuss recent developments of small molecule-based fluorophore-drug conjugates, including non-cleavable and cleavable ones, that are capable of visualizing drug delivery. 相似文献